DAPK1 and chronic granulomatous disease: Of interest, DAPK1 activity was defective in murine and human CGD (Oikonomou et al, 2016), a finding suggesting that the LAP/DAPK1 axis may represent a druggable pathway in CGD (Oikonomou et al, 2018).